<DOC>
	<DOCNO>NCT00668733</DOCNO>
	<brief_summary>The objective study obtain long-term sustained clearance rate subject previously treat imiquimod creams study GW01-0702 , GW01-0703 , GW01-0704 GW01-0705 .</brief_summary>
	<brief_title>Follow-up Study Evaluate Sustained Clearance Rates Actinic Keratoses One Year</brief_title>
	<detailed_description>This Phase 3 longitudinal observational study . Subjects previously enrol study GW01-0702 , GW01-0703 , GW01-0704 , GW01-0705 completely clear AK lesion select treatment area end-of-study visit return follow-up visit 6 12 month EOS visit recurrence AKs . The NCT number mention study : NCT00603798 - Studies GW01-0703 GW01-0705 NCT00605176 Studies GW01-0702 GW01-0704</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>Are willing able give inform consent ; Have successfully complete one follow study : GW010702 , GW01 0703 , GW010704 , GW010705 determine completely clear AK lesion EOS visit designate treatment area previous study Are willing participate study outpatient , make visit study center followup evaluation , agree comply study requirement . None . All subject meet inclusion criterion may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Actinic keratoses</keyword>
	<keyword>Dermatologic disease</keyword>
</DOC>